Fulcrum Therapeutics Inc

NASDAQ:FULC  
12.96
+0.41 (+3.27%)
Products, Regulatory

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism

Published: 12/06/2021 13:07 GMT
Fulcrum Therapeutics Inc (FULC) - Fulcrum Therapeutics® Announces Additional Hbg Mrna Induction From Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of Ftx-6058 for Sickle Cell Disease and New Preclinical Mechanism Data.
Fulcrum Therapeutics Inc - New Mechanism Data Demonstrate Potent Downregulation of Bcl11a and Myb, Key Repressors of Fetal Hemoglobin.
Fulcrum Therapeutics Inc - Achieved Mean 5.6-fold Hbg Mrna Induction at 20mg and Mean 6.2-fold at 30mg After 14 Days of Once-daily Dosing.
Fulcrum Therapeutics Inc - Ftx-6058 Continues to Be Well-tolerated and Achieved Maximal Hbg Mrna Induction at Higher Doses.
Fulcrum Therapeutics Inc - on Track to Initiate Enrollment in Phase 1b Clinical Trial of Ftx-6058 by End of 2021.
Fulcrum - to Submit Ind Application With FDA by End of 2021 to Support Initiation of Clinical Trial of Ftx-6058 in Additional Hemoglobinopathies.